Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...
The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...
BASEL, Switzerland, October 29 /PRNewswire/ -- A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly ...
ZURICH , Switzerland The Food and Drug Administration has approved Roche Holdings’ new drug Mircera, which is used for the treatment of anemia associated with chronic renal failure in adults, ...
US regulators have given the green light to Roche's new anaemia drug Mircera, but no launch across the Atlantic is likely for some time as the Swiss firm is embroiled in a legal dispute it is losing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback